Pharmaceuticals

Global Trastuzumab Biosimilars Market Forecast 2026–2035: Long-Term Growth Insights

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the trastuzumab biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Trastuzumab Biosimilars Market in 2030?

The trastuzumab biosimilars market has experienced considerable expansion in recent years. It is anticipated to increase from $6.9 billion in 2025 to $8.86 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 28.5%. The historical development in this market can be linked to a high incidence of HER2 positive breast cancer, the expiration of trastuzumab patent exclusivity, escalating oncology drug costs, established regulatory pathways for biosimilars, and the integration of oncology practices in hospitals.

The trastuzumab biosimilars market is anticipated to experience substantial expansion over the coming years. Its valuation is projected to reach $24.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 28.9%. This projected growth during the forecast period stems from factors such as the rising incidence of cancer, the broadening of indications to include gastric cancer, supportive reimbursement policies for biosimilars, increasing trust among physicians, and intensified efforts to control healthcare costs. Key trends expected within this period encompass the swift adoption of oncology biosimilars, enhanced availability of HER2-targeted therapies, competitive pricing strategies in breast cancer management, wider implementation of oncology services in hospitals, and an increasing willingness to switch to biosimilars.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

What Drivers Are Influencing Production Trends In The Trastuzumab Biosimilars Market?

The expansion of the trastuzumab biosimilars market was supported by the rising occurrence of breast and gastric cancer. Trastuzumab biosimilar is utilized in addressing human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. For instance, in September 2023, the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, estimated that around 297,790 new instances of invasive breast cancer would be identified in women in 2023, and approximately 43,700 women would perish from breast cancer in the same year. Furthermore, according to Cancer India, breast cancer stands as the most prevalent cancer among women in India, accounting for 14% of female cancer cases. Consequently, the increasing prevalence of breast and gastric cancer enhances the need for trastuzumab biosimilar, offering a more affordable alternative to expensive medicines, thereby stimulating the trastuzumab biosimilars market.

Which Segments Are Gaining Traction In The Trastuzumab Biosimilars Market?

The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products

2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

What Trends Are Reshaping The Dynamics Of The Trastuzumab Biosimilars Market?

Major players are continuously prioritizing the introduction of new products into untapped territories, which significantly shapes the trastuzumab biosimilars market. Companies operating within this market are undertaking various strategic initiatives such as developing new products, establishing partnerships, and broadening their geographical presence and product offerings. These actions aim to maintain their competitive standing and better address customer needs. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), for the treatment of several forms of HER2-Overexpressing Cancer. HERCESSI is specifically indicated for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. HER2-positive cancers are typically aggressive but show effective responses to targeted therapies. HERCESSI functions by attaching to the HER2 receptor, thereby impeding its activity and subsequently slowing down the multiplication of cancer cells.

Who Are The Major Companies Operating In The Trastuzumab Biosimilars Market?

Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Trastuzumab Biosimilars Market?

North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Trastuzumab Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3400&type=smp

Browse Through More Reports Similar to the Global Trastuzumab Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795